3d7 p. falciparum

Didesethyl chloroquine (Bisdesethylchloroquine) is an effective myocardial inhibitor. Didesethyl chloroquine (Bisdesethylchloroquine) is the main metabolite of the antimalarial drug chloroquine.

CWHM-1008 is an effective oral antimalarial drug. The EC50 values of the drug-sensitive Plasmodium falciparum 3D7 and drug-resistant Dd2 strains are 46 and 21 nM, respectively.

LysRs-IN-2 is a lysine tRNA synthetase (KRS) inhibitor with antiparasitic activity that inhibits Plasmodium falciparum KRS (PfKRS) and Cryptosporidium minum KRS (CpKRS), and is used in the study of malaria infections.

SARS-CoV-IN-1 is an effective SARS-CoV replication inhibitor with an EC50 of 4.9 μM in Vero cells.

SARS-CoV-IN-2 is an effective inhibitor of SARS-CoV replication.

SARS-CoV-IN-3 is an effective inhibitor of SARS-CoV replication.

DSM265 (PfSPZ) is a dihydroorotic acid dehydrogenase inhibitor with antimalarial activity (IC50: 8.9 nM).DSM265 inhibits the growth of Pf3D7 parasites and can be used for the treatment and prophylaxis of malaria infections.

WJM280 is an orally active antimalarial compound with an EC50 of 0.04 μM against the parasite P. falciparum 3D7.

SPB07935 inhibits plasmepsin II in the malaria-causing parasite Plasmodium falciparum and serves as an antimalarial agent. It affects the life cycle of P. falciparum, hindering the growth of the parasite's FcB1 and 3D7 strains, with IC50 values of 8 μM and 4.7 μM, respectively.

HDAC-IN-88 (Compound HJ-9) is a potent inhibitor of HDAC, effectively targeting HDAC6, HDAC1, HDAC2, HDAC8, and HDAC3 with IC50 values of 0.226, 1.103, 2.308, 3.255, and 3.864 μM, respectively. This compound suppresses the proliferation of cancer cells HepG2, HCT116, and MV4-11 with IC50 values of 5.47, 9.78, and 0.38 μM, respectively. Additionally, it inhibits the migration of HCT116 cells, causes cell cycle arrest at the G0/G1 phase, and induces apoptosis and autophagy in MV4-11 cells. HDAC-IN-88 reduces ROS levels and mitochondrial membrane potential and demonstrates antimalarial activity by inhibiting Plasmodium falciparum 3D7 with an EC50 of 165 nM. Furthermore, HDAC-IN-88 exhibits anti-angiogenic properties.

CCOE-5 is a chalcone derivative with antimalarial activity, exhibiting an IC50 of 1.4 μg/mL against P. falciparum (3D7) and an IC50 of less than 5 μg/mL against P. falciparum (INDO). CCOE-5 shows potential for research in the anti-infective domain.

DSM1465 (Compound 82) is a potent and selective inhibitor of P. falciparum dihydroorotate dehydrogenase (PfDHODH) with an IC50 value of 15 nM. It inhibits P. falciparum 3D7 (Pf3D7) parasites with an EC50 value of 1.4 nM and demonstrates significant in vivo efficacy in humanized P. falciparum mouse models.

1. Dehydrocorydaline(DHC) not only inhibits antibody-mediated allergic reactions but also influences cell-mediated allergic reactions, and the inhibitory effect of Corydalis Tuber on allergic reactions may be partially attributed to DHC. 2. Dehydrocorydal

AN3661, a potent antimalarial lead compound, targets a Plasmodium falciparum cleavage and polyadenylation specificity factor homologue subunit 3 (PfCPSF3) and inhibits Plasmodium falciparum laboratory-adapted strains, Ugandan field isolates, and murine P. berghei and P. falciparum infections[1].

Purfalcamine is an orally active, selective Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) inhibitor with an IC50 of 17 nM and an EC50 of 230 nM, exhibiting antimalarial activity by inducing developmental arrest of malaria parasites at the schizont stage[1][2].

JMI-346 can be used as an anti-malarial agent that inhibits the P. falciparum strains CQS (3D7) and CQR (RKL-9) growth with IC50 values of 13 μM and 33 μM. JMI-346 is a potent inhibitor of Plasmodium falciparum falcipain-2 protease (PfFP-2) [1].

JMI-105 has the potential as an antimalarial agent. JMI-105 is a potent inhibitor of Plasmodium falciparum falcipain-2 protease (PfFP-2) that inhibits the P. falciparum strains CQ S (3D7) and CQ R (RKL-9) growth with IC 50 values of 8.8 μM and 14.3 μM. In a murine model with P. berghei ANKA infection, JMI-105 significantly decreases parasitemia and prolonged host survival [1].

WAY-309236 is a bioactive biochemical reagent exhibiting inhibitory activity against both drug-sensitive (3D7) and drug-resistant (W2) strains of Plasmodium falciparum, with IC50 values of 275 nM and 279 nM, respectively.

Phosphodiesterase-IN-1 (Compound 7), a phosphodiesterase (PDE) inhibitor, exhibits anti-Plasmodium and antiproliferative activities. It effectively inhibits P. falciparum (strain 3D7) with an IC 50 value of 0.64 μM [1].

INE963 demonstrates potent cellular activity against Pf 3D7 (EC50 = 6 nM) and achieves "artemisinin-like" kill kinetics in vitro with a parasite clearance time of <24 h. INE963 is also potent against P. falciparum and P. vivax clinical isolates from Brazil and Uganda with EC50's ranging from 0.01 to 7.0 nM

Melicopine is an alkaloid found in Z. simulans, known for its antimalarial and anticancer properties. It inhibits P. falciparum strains, including chloroquine-sensitive 3D7 (IC50 of 29.7 µg/mL) and chloroquine-resistant Dd2 (IC50 of 33.7 µg/mL). Additionally, Melicopine exhibits cytotoxicity against prostate cancer cells PC-3M (IC50 of 47.9 µg/mL) and LNCaP (IC50 of 37.8 µg/mL), but it is inactive in non-cancerous HEK293 cells (IC50 greater than 100 µg/mL). Melicopine holds potential for research in anticancer and anti-infective applications.